There are a number of paid research reports on market size for cardiotoxicity. Below just reconfirmed that about 40% o
f breast cancer patients could be at risk of cardiotoxicity due to chemo treatment.
Plenty of articles confirm the cardiotoxicity due to Doxorubicin etc., eg:
https://www.nature.com/articles/srep44735.pdf
https://www.tandfonline.com/doi/full/10.1080/14740338.2021.1906860?scroll=top&needAccess=true
https://heart.bmj.com/content/heartjnl/102/Suppl_6/A14.2.full.pdf
Just the cardiotoxicity testing market is expected to be about $2.4Bn in 2023, can you even imagine the cardiotoxicity treatment market size?
https://www.businesswire.com/news/home/20200108005272/en/Global-In-Vitro-Toxicity-Testing-Market-2019-2023-Evolving-Opportunities-with-Abbott-Laboratories-and-Agilent-Technologies-Inc.-Technavio
Ann: Breakthrough Zantrene Heart Protection Discovery, page-144
-
- There are more pages in this discussion • 223 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.83 |
Change
-0.030(1.61%) |
Mkt cap ! $311.7M | |||
| Open | High | Low | Value | Volume |
| $1.86 | $1.91 | $1.79 | $169.3K | 92.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 92 | $1.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.87 | 3472 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |